SARS-CoV-2 VLP Vaccine
/ Bilkent University, Nobel Pharmaceuticals
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 31, 2022
VLP-58-1023-Al-K3-PII: Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine
(clinicaltrials.gov)
- P2 | N=349 | Completed | Sponsor: Ihsan GURSEL, PhD, Prof. | Recruiting ➔ Completed | Trial completion date: Sep 2022 ➔ Jan 2022
Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG
May 25, 2022
Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults
(clinicaltrials.gov)
- P1 | N=38 | Completed | Sponsor: Ihsan GURSEL, PhD, Prof. | Recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG • IL4
1 to 2
Of
2
Go to page
1